A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Merus N.V. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 2,749,401 shares of MRUS stock, worth $141 Million. This represents 3.41% of its overall portfolio holdings.

Number of Shares
2,749,401
Previous 2,649,401 3.77%
Holding current value
$141 Million
Previous $119 Million 36.36%
% of portfolio
3.41%
Previous 2.46%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$39.81 - $60.2 $3.98 Million - $6.02 Million
100,000 Added 3.77%
2,749,401 $163 Million
Q1 2024

May 15, 2024

SELL
$28.03 - $51.82 $10.4 Million - $19.2 Million
-370,500 Reduced 12.27%
2,649,401 $119 Million
Q4 2023

Feb 14, 2024

SELL
$20.06 - $28.66 $17.2 Million - $24.6 Million
-857,037 Reduced 22.11%
3,019,901 $83 Million
Q3 2023

Nov 14, 2023

BUY
$20.13 - $27.29 $17 Million - $23.1 Million
845,000 Added 27.87%
3,876,938 $91.4 Million
Q2 2023

Aug 14, 2023

BUY
$18.33 - $27.18 $11.9 Million - $17.7 Million
651,500 Added 27.37%
3,031,938 $79.8 Million
Q4 2022

Feb 14, 2023

SELL
$12.8 - $23.66 $1.81 Million - $3.34 Million
-141,115 Reduced 5.6%
2,380,438 $36.8 Million
Q3 2022

Nov 14, 2022

BUY
$18.64 - $28.93 $9.98 Million - $15.5 Million
535,629 Added 26.97%
2,521,553 $50.5 Million
Q2 2022

Aug 15, 2022

BUY
$13.98 - $29.25 $21.7 Million - $45.3 Million
1,548,924 Added 354.44%
1,985,924 $45 Million
Q4 2021

Feb 14, 2022

BUY
$20.0 - $32.29 $8.74 Million - $14.1 Million
437,000 New
437,000 $13.9 Million

Others Institutions Holding MRUS

About Merus N.V.


  • Ticker MRUS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,878,200
  • Market Cap $2.35B
  • Description
  • Merus N.V., a clinical-stage immuno-oncology company, engages in the discovery and development of bispecific antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer, as well as in Phase...
More about MRUS
Track This Portfolio

Track Deerfield Management Company, L.P. (Series C) Portfolio

Follow Deerfield Management Company, L.P. (Series C) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Deerfield Management Company, L.P. (Series C), based on Form 13F filings with the SEC.

News

Stay updated on Deerfield Management Company, L.P. (Series C) with notifications on news.